Exscientia

Exscientia was a pioneer in using AI to design drug molecules that reached clinical trials, becoming one of the first companies to advance an AI-designed compound into human testing. The company combined active learning algorithms with automated chemical synthesis to iteratively design and optimize drug candidates. In 2024, Exscientia was acquired by Recursion Pharmaceuticals in a $688M deal, merging two of the leading AI drug discovery platforms.

Multiple AI-designed compounds in Phase 1; now part of Recursion

Precision-designed drug molecules using active learning and experimental feedback loops. Exscientia's platform iteratively designed and tested molecules, reducing the typical drug design timeline from years to months. Now integrated into Recursion's broader platform.